1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Ovarian Cancer: KOL Insight

Ovarian Cancer: KOL Insight

  • April 2018
  • ID: 5438881
  • Format: PDF
  • By Firstword Pharma

Summary

Table of Contents

How will new combination regimens impact the ovarian cancer treatment landscape?

PARP inhibitors are firmly entrenched in the treatment algorithm for ovarian cancer, and their role continues to diversify. How will oncologists choose between AstraZeneca/Merck & Co.’s Lynparza, Tesaro/Merck & Co.’s Zejula and Clovis’ Rubraca which are now all indicated for the maintenance treatment of recurrent tumours and will the role of BRCA mutation testing diminish? Furthermore, as competition gravitates towards the first-line setting, how do KOLs compare and contrast the multitude of combination regimens vying for approval in this lucrative indication? Immunotherapies are still lagging behind in ovarian cancer, compared with certain other malignancies, but which key trials could finally place them on map? Meanwhile, what opportunities and threats lie ahead for Roche’s Avastin, a well-established standard of care? And could ImmunoGen’s mAb-drug conjugate mirvetuximab soravtansine also play a role? Twelve of the world’s leading KOLs from the US and Europe offer candid insights on four marketed therapies and nine Phase III drugs.

Take a tour of the report now
• The table of contents >
• The key business questions answered >
• The key KOL quotes >
• See the therapies covered >
• Find out who the 6 EU & 6 US KOLs are >
• Review an extract from the report - 1 drug profile>

Top takeaways
• Could first-line treatment become the next battleground for novel treatment strategies in ovarian cancer? With a number of companies investing in multiple combination regimens, who could emerge victorious?
• What potential do immune checkpoint inhibitors hold in the future treatment of ovarian cancer? Roche, Merck Group and Pfizer are heavily invested in this area, but how do KOLs rate the prospects for combination regimens containing avelumab or atezolizumab?
• PARP inhibitors comprise a cornerstone of treatment for advanced ovarian cancer'How do KOLs see their use evolving?
• AstraZeneca/Merck & Co.’s Lynparza is well established in relapsed disease. But is increasing competition, or the outcome of the PAOLA-1 trial, likely to impact its use?
• As the treatment paradigm matures and PARP inhibitors gain a broader role, what do KOLs see as the key threats and opportunities for Tesaro/Merck & Co.’s Zejula and Clovis’ Rubraca?
• Roche’s Avastin is firmly entrenched in the treatment algorithm for ovarian cancer. But what opportunities and threats lie ahead?
• Allergan/Amgen’s Mvasi is making headlines as the first bevacizumab biosimilar to gain approval. How well accepted will it be among oncologists who treat ovarian cancer and how is pricing likely to influence uptake?
• Could ImmunoGen’s antibody-drug conjugate IMGN853 have a potential role in ovarian cancer? KOLs debate the potential advantages and pitfalls to this novel approach to treatment.
• Gradalis’ therapeutic vaccine, Vigil, could lead the way in personalised medicine for ovarian cancer. Do KOLs anticipate that its therapeutic benefit will outweigh logistical challenges and potentially high costs?

Quotes
“If we have three negative trials, let’s say - JAVELIN 200, JAVELIN 100, the ATALANTE trial - people are going to really begin questioning if immunotherapy has a role. Then we have the next wave of trials with checkpoint and PARP together.” US Key Opinion Leader

“Now we’ve got choices. The issue will be what’s the optimal use of some of these agents? So, we use PARP inhibitors up front? If we do, is it for germline or is it somatic? Or do we use HRD assays? When do we use bevacizumab? Ovary is finally getting to where lung and breast cancer have been for quite a while.” US Key Opinion Leader

Sample of therapies covered

Marketed Therapies
• Lynparza (olaparib; AstraZeneca/Merck & Co.
• Zejula (niraparib; Tesaro/Merck & Co.
• Rubraca (rucaparib; Clovis)
• Avastin (bevacizumab; Roche)

Phase III Therapies
• Veliparib (ABT-888; AbbVie
• Atezolizumab (Tecentriq; Roche)
• Avelumab (Bavencio; Merck Group/Pfizer)
• Vigil (autologous tumour cell vaccine; Gradalis)
• Nintedanib (Vargatef; Boehringer Ingelheim)
• Ofranergene obadenovec (VB-111; VBL Therapeutics)
• Mvasi (bevacizumab biosimilar; Allergan/Amgen)
• Masitinib (AB Science)
• Mirvetuximab soravtansine (IMGN853; ImmunoGen)

KOLs interviewed

KOLs from North America
• Ronald Alvarez,Professor and Chairman of the Department of Obstetrics & Gynaecology, Vanderbilt University Medical Centre, Nashville, TN.
• Michael J. Birrer, Professor and Director, Gynaecologic Medical Oncology Massachusetts General Hospital Leader, DF/HCC Gynaecologic Cancers Program, Boston, MA.
• Robert A. Burger,Professor of Obstetrics & Gynaecology, Director of Clinical Research and Fellowship Program in Gynaecologic Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA.
• Robert L. Coleman, Professor, Vice Chair of Clinical Research and Ann Rife Cox Chair in Gynaecology, Department of Gynaecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Centre, Houston, TX.
• Thomas Herzog,Deputy Director of the University of Cincinnati Cancer Institute, Professor of Obstetrics & Gynaecology at the University of Cincinnati Cancer Institute, Cincinnati, OH
• Bradley J. Monk,Professor and Director of the Division of Gynaecologic Oncology, Creighton University School of Medicine, St. Joseph’s Hospital and Medical Centre, Phoenix, AZ.

KOLs from Europe
• Stan Kaye, Professor and Consultant Medical Oncologist, Head of the Division of Clinical Studies at the Institute of Cancer Research, London, UK.
• Jean-Emmanuel Kurtz, Professor and hospital practitioner at the University of Strasbourg/ University Hospital Strasbourg, Strasbourg, France.
• Christian Marth, Director of Obstetrics and Gynaecology, University Hospital Innsbruck, Innsbruck, Austria.
• Sandro Pignata, Head of Uro-Gynaecological Department, Division of Medical Oncology, IRCCS National Cancer Institute, Naples, Italy.
• Isabelle Ray Coquard, Professor of Medical Oncology and President of the GINECO group, University Claude Bernard, Lyon, France.
• Leading German KOL, Clinic Director at a major university hospital, Germany.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Chronic Urticaria Or Hives - Pipeline Review, H2 2019

Chronic Urticaria Or Hives - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Chronic Urticaria Or Hives - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Chronic Urticaria Or Hives - Pipeline Review, H2 2019, provides an overview of ...

Interleukin 1 - Pipeline Review, H1 2020

Interleukin 1 - Pipeline Review, H1 2020

  • $ 3500
  • January 2020

Interleukin 1 - Pipeline Review, H1 2020SummaryInterleukin 1 (IL1) pipeline Target constitutes close to 24 molecules. Out of which approximately 23 molecules are developed by companies and remaining by ...

Hematopoietic Stem Cell Transplantation Global Clinical Trials Review, H1, 2020

Hematopoietic Stem Cell Transplantation Global Clinical Trials Review, H1, 2020

  • $ 2500
  • January 2020

Hematopoietic Stem Cell Transplantation Global Clinical Trials Review, H1, 2020Summaryclinical trial report, “Hematopoietic Stem Cell Transplantation Global Clinical Trials Review, H1, 2020" provides ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market in New Zealand

  • February 2020
    36 pages
  • Therapy  

    Targeted Therap...  

    Monoclonal Anti...  

  • New Zealand  

    Oceania  

View report >

Hormone and Therapy Market in Pakistan and the US

  • February 2020
    7 pages
  • Hormone  

    Therapy  

    Diabetes  

  • Pakistan  

    United States  

    Netherlands  

View report >

Vaccine Market and Influenza Statistics in the US and India

  • February 2020
    6 pages
  • Vaccine  

    Influenza  

    Hospital  

  • United States  

    India  

View report >

Analgesic Market 6 days ago

Therapy Market 7 days ago


ref:plp2018

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on